The global market for insulin is expected to
reach USD 47.54 billion by 2020, according to a new study by Grand View
Research, Inc. Growing global prevalence of type I and type II diabetes and the
presence of high unmet needs in emerging markets such as India and China are
expected to be two of the most significant growth drivers of this market.
Moreover, increasing incidence rates of lifestyle induced diseases such as
obesity and growing global geriatric population base are expected to serve the
global insulin market as drivers.
The global intermediate and long acting insulin
segments were two of the largest markets in 2013 and together accounted for
over 45% of the overall revenue. Higher efficacy exhibited by these segments in
terms of insulin peak time is one of the major factors accounting for their
large market shares.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/insulin-market
Further key findings from the study
suggest:
- Insulin analogs were the most dominant source in 2013 and accounted for over 70% of the revenue. These products are rapidly substituting the human recombinant insulin products by exhibiting higher efficacy.
- North America was the largest regional market in 2013, accounting for over 40% of global revenue. The presence of sophisticated healthcare infrastructure, high type I diabetes prevalence and patient disposable incomes in this region are some of the factors expected to drive market growth. Emerging markets including Asia Pacific accounted for 26.5% of global revenue in 2013.
- Asia Pacific insulin market is expected to grow at the highest CAGR of over 15% from 2014 to 2020 on account of the presence of high unmet medical needs pertaining to diabetes and increasing healthcare expenditures in emerging markets such as India and China
- Key industry participants include Sanofi, Novo Nordisk, Eli Lilly, Novartis, Biocon, Oramed Pharmaceuticals, Bristol-Myers Squibb, Takeda Pharmaceuticals, Dongbao Enterprise Group Co., Ltd. and others.
Browse All Reports of
this category @ http://www.grandviewresearch.com/industry/pharmaceuticals
For the purpose of this study, Grand View Research
has segmented the global insulin market on the basis of product, segment (on
the basis of source), application and region:
Insulin Product
Outlook
•
Fast Acting Insulin
•
Short Acting Insulin
•
Intermediate Acting Insulin
•
Long Acting Insulin
•
Pre-Mixed Insulin
Insulin Segment
(on the basis of source) Outlook
•
Insulin Analogs
•
Human Recombinant Insulin
Insulin
Application Outlook
•
Insulin for Type I Diabetes
•
Insulin for Type II Diabetes
Insulin Regional
Outlook
•
North America
•
Europe
•
Asia Pacific
•
RoW
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Blog
Site: http://www.divog.org/
No comments:
Post a Comment